Tuesday, November 17, 2015
Array BioPharma and Pierre Fabre are collaborating to globally develop and commercialize Array’s late-stage novel oncology products binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, currently are advancing in three global phase III trials for melanoma and ovarian cancer. Top-line results from NEMO, a phase III study of binimetinib in patients with NRAS-mutant melanoma, are anticipated before the end of 2015.
ImmunoCellular Therapeutics has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as professor, department of melanoma medical oncology, division of cancer medicine, as well as professor, department of immunology, division of cancer medicine, and director, solid tumor cell therapy, center for cancer immunology research, at MD Anderson.
The European Society of Clinical Microbiology and Infectious Disease (ESCMID), a nonprofit organization that explores the risks and best practices in infectious disease, has in recent years been very active in the area of antimicrobial resistance. It is now calling on individual European nations to join its battle.
The American Heart Association (AHA) and Google Life Sciences (GLS) have announced a joint commitment to form a research collaboration that will bring new, unconventional thinking to one of the longstanding challenges of cardiovascular disease. Each organization will invest $25 million for a total of $50 million over roughly five years to support novel strategies to understand, prevent and reverse coronary heart disease and its consequences, such as heart failure and sudden cardiac death.
Ninety-four percent of 100 senior executives at life sciences surveyed are planning to make an acquisition in the next year, with 91% of U.S. respondents expecting them to be cross-border transactions. The global study was conducted by global law firm Reed Smith, in partnership with Mergermarket.
Janssen Pharmaceuticals has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase I and expected to enter phase II studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.